使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to today's DexCom first quarter year 2008 earnings conference. Today's call is being recorded.
各位好,歡迎參加 DexCom 2008 年第一季財報電話會議。今天的電話會議將被錄音。
At this time, I'd like to turn the conference over to your host, Terry Gregg, President and CEO.
此刻,我想將會議交給今天的主持人、總裁兼執行長 Terry Gregg。
Please go ahead.
請開始。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thank you, operator, and thanks, all of you, for joining us today.
謝謝接線員,也謝謝各位今天加入我們。
On our side I have Steve Pacelli, who is Senior Vice President Corporate Affairs; Jess Roper, our Chief Financial Officer.
我們這邊有資深副總裁(企業事務)Steve Pacelli,以及我們的財務長 Jess Roper。
I'd like Steve to start the conference call with the safe-harbor statement.
我想請 Steve 先以安全港聲明開始今天的電話會議。
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Thanks, Terry.
謝謝你,Terry。
Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's expectations about future events, operating plans, and performance, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements are detailed under Risk Factors and elsewhere in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and our other reports filed with the SEC. We undertake no obligation to update publicly or revise these forward-looking statements for any reasons.
我們在今天電話會議中所做的部分陳述,可能構成前瞻性陳述。這些陳述反映管理層對未來事件、營運計畫與績效的預期,且僅截至本日有效。這些前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何此等前瞻性陳述所明示或暗示者存在重大差異的因素清單,已在我們的 Form 10-K 年度報告、Form 10-Q 季度報告以及向美國證券交易委員會(SEC)提交的其他報告中的「風險因素」及其他章節中詳述。我們不承擔因任何原因公開更新或修訂這些前瞻性陳述的義務。
Terry?
Terry?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Steve.
謝謝你,Steve。
The agenda today, we're going to start off with Jess giving us a financial review. Then we'll move into commercial and reimbursement updates, talk about our partnerships with the insulin-pump entities, give you a head's up and review of what research and development and a regulatory update. We'll finish off with an in-hospital continuous glucose monitoring review, summarize, and then we'll move into Q&A.
今天的議程,我們會先由 Jess 進行財務回顧。接著我們會進入商業與給付(reimbursement)最新進展,談談我們與胰島素幫浦業者的合作夥伴關係,並先行提示與回顧研發與法規(regulatory)更新。我們將以院內連續血糖監測的回顧作結、進行總結,然後進入問答。
So let's start with Jess.
那我們先從 Jess 開始。
Jess Roper - CFO
Jess Roper - CFO
Great. Thank you, Terry.
很好,謝謝你,Terry。
DexCom reported product revenues of $1.8 million for the first quarter of 2008, compared to $1 million in 2007.
DexCom 2008 年第一季產品營收為 180 萬美元,較 2007 年的 100 萬美元增加。
Sequentially product revenue increased over 19% from the fourth quarter of 2007. We sold over 1,207 system starter kits during Q1.
按季比較,產品營收較 2007 年第四季成長超過 19%。第一季我們售出超過 1,207 套系統入門套組(starter kits)。
As of March 31, 2008, we have upgraded up over 1,500 first-generation three-day customers to our second-generation Seven product.
截至 2008 年 3 月 31 日,我們已將超過 1,500 名第一代三日型客戶升級至第二代 Seven 產品。
Sensor revenues were up over 23% sequentially from Q4 of 2007. A very small portion of our Q1 2008 sensor sales included first-generation three-day sensors.
感測器營收較 2007 年第四季按季成長超過 23%。我們 2008 年第一季的感測器銷售中,僅有極小部分包含第一代三日型感測器。
Total revenue for the first quarter of 2008 was $1.9 million and included a small amount of development grant revenue. As you may recall, we entered into a joint-development agreement with Animas Corporation in January of 2008, whereby Animas would contribute up to $750,000 towards development efforts related to an integrated pump CGM system. Based on terms of the agreement and cash received thus far, we anticipate recognizing development grant revenue and also corresponding development cost of sales throughout the term of the agreement.
2008 年第一季總營收為 190 萬美元,其中包含少量開發補助收入。如各位所記得,我們於 2008 年 1 月與 Animas Corporation 簽訂共同開發協議,依該協議 Animas 將就整合式幫浦 CGM 系統相關的開發工作,提供最高 75 萬美元的開發資助。根據協議條款及目前已收到的現金,我們預期在協議期間內認列開發補助收入,並同時認列相對應的開發銷貨成本。
Cost of sales for the first quarter of 2008 totaled $3.2 million, compared to $3.1 million for the first quarter in 2007. The increase was primarily due to $130,000 in development cost of sales incurred in Q1 of 2008.
2008 年第一季銷貨成本合計 320 萬美元,較 2007 年第一季的 310 萬美元增加。增加主要來自 2008 年第一季發生的 13 萬美元開發銷貨成本。
The increase in direct cost of sales relating to additional product sales was offset by lower direct labor costs and increased fixed overhead absorption.
與額外產品銷售相關的直接銷貨成本增加,被較低的直接人工成本與固定製造費用吸收增加所抵銷。
Our gross margin loss for the first quarter of 2008 was $1.4 million, compared to a loss of $2.1 million in 2007.
2008 年第一季毛利損失為 140 萬美元,較 2007 年的 210 萬美元損失改善。
Research and development expense increased by approximately $800,000 to $4.8 million for the first quarter in '08, compared to $4 million in 2007. Major elements of R&D expense included increased facilities costs, supplies, and share-based compensation.
2008 年第一季研發費用增加約 80 萬美元至 480 萬美元,較 2007 年的 400 萬美元增加。研發費用的主要項目包括設施成本、耗材以及股份基礎給付(share-based compensation)增加。
Selling, general and administrative expense totaled $6.4 million in Q1 of 2008, compared to $5.4 million in 2007. The approximate $1 million increase was primarily due to additional general and administrative costs. Major components of SG&A expense include $640,000 in higher share-based compensation, $252,000 in additional sales commissions.
2008 年第一季銷售、一般及行政費用(SG&A)合計 640 萬美元,較 2007 年的 540 萬美元增加。約 100 萬美元的增幅主要來自額外的一般及行政成本。SG&A 費用的主要組成包括股份基礎給付增加 64 萬美元,以及額外銷售佣金 25.2 萬美元。
Net interest expense increased by approximately $850,000 for the first quarter of 2008 to $328,000 compared to net interest income of $527,000 in 2007. The increase in net interest expense was primarily due to additional interest expense relating to the $60 million in convertible senior notes that was outstanding for the entire first quarter of 2008, as compared to being outstanding for less than one month during the same quarter of 2007.
2008 年第一季淨利息費用約增加 85 萬美元至 32.8 萬美元,而 2007 年同期為淨利息收入 52.7 萬美元。淨利息費用增加主要是因為 6,000 萬美元可轉換優先票據(convertible senior notes)在 2008 年第一季全季均為流通在外;相較之下,2007 年同季僅有不到一個月為流通在外。
Our net loss increased to $13 million for the first quarter of 2008, compared to $10.9 million in 2007. Of the $2.1 million increase in net loss, there was $1.2 million in additional noncash expense relating primarily to share-based compensation, depreciation and amortization. Additionally, we incurred approximately $850,000 in additional net interest expense during the first quarter of 2008, as compared to the same quarter of 2007.
2008 年第一季淨損失增加至 1,300 萬美元,較 2007 年的 1,090 萬美元增加。在淨損失增加的 210 萬美元中,有 120 萬美元為額外的非現金費用,主要與股份基礎給付、折舊與攤銷相關。此外,2008 年第一季我們亦較 2007 年同季多發生約 85 萬美元的淨利息費用。
During the quarter we invested $1.1 million in capital equipment and facilities to support our business. In January of 2008, we amended our equipment line that allows us to borrow an additional $3 million for the purchase of equipment and other related items. As of March 2008, we had fully drawn on our $3 million equipment line.
本季我們投資 110 萬美元於資本設備與設施以支援業務。2008 年 1 月,我們修訂設備授信額度,使我們可額外借款 300 萬美元用於購置設備及其他相關項目。截至 2008 年 3 月,我們已全數動用 300 萬美元的設備授信額度。
We ended the quarter with $56 million in cash, marketable securities, and restricted cash, and had working capital of $46 million.
本季期末我們持有 5,600 萬美元的現金、可出售有價證券及受限制現金,營運資金為 4,600 萬美元。
I would like to now turn it back to our CEO and President, Terry Gregg.
我現在把時間交回給我們的總裁兼執行長 Terry Gregg。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Jess.
謝謝你,Jess。
Before we jump into our commercial update, in light of recent news, we thought it would be appropriate to begin today's call with an update on our reimbursement efforts and the continued momentum we see building in both the adoption of coverage policies for CGM by third-party payers and in our willingness to enter into contracts with DexCom to cover our CGM products.
在我們進入商業最新進展之前,鑑於近期消息,我們認為先以給付(reimbursement)工作的更新作為今天電話會議的開場是合適的;同時也更新我們在兩方面持續看到的動能:第三方付款方對 CGM 採納承保政策,以及他們願意與 DexCom 簽訂合約以承保我們 CGM 產品。
We were extremely pleased to learn in April that the Anthem WellPoint network of Blue Cross providers has adopted a positive coverage decision regarding CGM. I would like to spend a few minutes discussing what this decision means for CGM as a category and, more specifically, for DexCom.
我們在 4 月得知 Anthem WellPoint 的 Blue Cross 供應商網路已就 CGM 採納正面的承保決定,對此我們感到非常高興。我想花幾分鐘說明這項決定對 CGM 這個品類,以及更具體地對 DexCom 的意義。
First, to qualify for coverage, patients must demonstrate medical necessity, which is defined in the Anthem WellPoint policy to include type 1 patients who have recurring episodes of hypoglycemia and who are otherwise unable to achieve glycemic control despite either wearing an insulin pump or taking three or more insulin injections per day and regularly monitoring their glucose levels by taking four or more finger-stick measurements per day. Pregnant women with type 1 diabetes are also covered by this policy.
首先,要符合承保資格,患者必須證明醫療必要性。Anthem WellPoint 的政策將醫療必要性定義為:第一型糖尿病患者若反覆發生低血糖,且即使使用胰島素幫浦或每日注射胰島素三次以上,並且透過每日四次以上指尖採血(finger-stick)規律監測血糖,仍無法達到血糖控制者,即符合條件。第一型糖尿病孕婦亦在此政策承保範圍內。
While limited in scope, we believe this coverage policy is an important first step to achieving broad-base coverage for CGM as a category and parallels the adoption of coverage policies for insulin pumps when they were first reimbursed.
儘管範圍有限,我們認為這項承保政策是推動 CGM 作為一個品類取得廣泛承保的重要第一步,並且與胰島素幫浦在最初開始獲得給付時承保政策的採納情況相呼應。
We also caution that it is likely to take time for patients and their physicians to learn about this coverage decision, demonstrate medical necessity, and ultimately receive reimbursement for their CGM products.
我們也提醒各位,患者及其醫師可能需要一段時間才能了解這項承保決定、證明醫療必要性,並最終取得其 CGM 產品的給付。
Furthermore, as it relates to DexCom, this coverage decision does not mean our products are immediately reimbursed by Anthem WellPoint. We must now work within the Anthem WellPoint network to negotiate contracts to cover our products.
此外,就 DexCom 而言,這項承保決定並不代表 Anthem WellPoint 會立即給付我們的產品。我們現在必須在 Anthem WellPoint 網路內進行合作,協商承保我們產品的合約。
In summary, the Anthem WellPoint decision was adopted and released much earlier than expected, as we had previously guided that we expected to see at least one large national payer adopt a positive coverage decision before the end of 2008. We believe that other large payers will be influenced by the Anthem WellPoint coverage decision and that this decision could accelerate the adoption of similar coverage policies in the next several quarters.
總結而言,Anthem WellPoint 的決定比預期更早採納並發布,因為我們先前曾指引,預期在 2008 年底前至少會看到一家大型全國性付款方採納正向的給付涵蓋決策。我們相信,其他大型付款方將受到 Anthem WellPoint 給付涵蓋決策的影響,而此決策可能在接下來幾個季度加速類似給付涵蓋政策的採用。
Our mission for the balance of 2008 is to continue to educate the private-payer community on the role of CGM in assisting patients to better manage their glucose excursions and to work to obtain additional coverage decisions for CGM and to enter into contracts with payers to reimburse our products.
我們在 2008 年剩餘期間的使命,是持續向民間付款方社群宣導 CGM 在協助患者更好管理其血糖波動方面的角色,並努力取得更多 CGM 的給付涵蓋決策,同時與付款方簽訂合約以報銷我們的產品。
We continue to see reimbursement as one of the key challenges to achieving widespread adoption of CGM, and although we are extremely pleased with the fact that a significant national payer such as Anthem WellPoint has taken the lead in adopting a positive coverage decision, we reiterate that it will take time for this and other positive coverage decisions to filter down to patients and physicians and translate into sales, and it will take time for DexCom to secure contracts with these payers as coverage decisions are released.
我們仍將報銷視為實現 CGM 廣泛採用的關鍵挑戰之一。儘管我們對 Anthem WellPoint 這樣的重要全國性付款方率先採納正向給付涵蓋決策感到非常欣慰,但我們再次強調,這項及其他正向給付涵蓋決策需要時間才能向下傳導至患者與醫師並轉化為銷售;同時,隨著給付涵蓋決策陸續發布,DexCom 也需要時間與這些付款方簽訂合約。
Highlighting some key performance metrics for the first quarter of 2008, total revenue grew approximately 22% sequentially from Q4 2007 to Q1 2008. We sold over 1,200 starter kits for The Seven in the first quarter, amounting to a 45% increase in starter-kit sales compared to Q4 2007.
就 2008 年第一季的一些關鍵績效指標而言,總營收自 2007 年第四季至 2008 年第一季按季成長約 22%。第一季我們售出超過 1,200 套 The Seven 入門套件,較 2007 年第四季的入門套件銷售量增加 45%。
In addition, as of the end of Q1 '08, we have successfully upgraded a total over 1,500 of our STS three-day customers to The Seven system. However, we expect upgrades to fall off sharply in Q2, as we look to discontinue production of the STS three-day entirely by the end of this quarter.
此外,截至 2008 年第一季末,我們已成功將累計超過 1,500 位 STS 三日型客戶升級至 The Seven 系統。然而,我們預期第二季的升級將大幅下滑,因為我們計畫在本季末前完全停止 STS 三日型的生產。
Finally, we continue to be encouraged about the long-term viability of the business, as we are pleased to report an increase of over 23% in sensor revenues quarter to quarter.
最後,我們對業務的長期可行性仍感到鼓舞,因為我們很高興報告感測器營收按季成長超過 23%。
As we look to the remainder of 2008, we will continue to focus our selling efforts on approximately the largest hundred diabetes centers in the U.S. However, we expect to broaden our reach to include centers which are geographically aligned with payers who have adopted coverage policies for CGM.
展望 2008 年剩餘期間,我們將持續把銷售重點放在美國約前一百大的糖尿病中心。然而,我們預期將擴大觸及範圍,納入在地理位置上與已採納 CGM 給付涵蓋政策之付款方相對應的中心。
At the present time, we continue to believe our sales force is appropriately sized at approximately 45 field-based individuals. However, we may look to expand the size of the sales force based on additional positive momentum on the reimbursement front.
目前,我們仍認為我們的銷售團隊規模適當,約為 45 名外勤人員。不過,若報銷方面出現更多正向動能,我們可能會考慮擴編銷售團隊。
As we previously discussed in January of this year, we announced two separate development agreements -- one with Animas Corporation, a division of J & J, and one with Insulet Corporation -- to develop integrated insulin-pump CGM systems. We have made considerable development progress to date. For example, our project development teams have already produced a working prototype of a sensor-integrated insulin pump, and we have recently demonstrated the user interface, including various menu screens and glucose tracking output, to members of the Food and Drug Administration.
如同我們今年 1 月先前所討論,我們宣布了兩項獨立的開發協議——一項與 Animas Corporation(J & J 旗下部門)簽訂,另一項與 Insulet Corporation 簽訂——以開發整合式胰島素幫浦 CGM 系統。迄今我們已取得相當可觀的開發進展。例如,我們的專案開發團隊已製作出可運作的感測器整合式胰島素幫浦原型機,且我們近期已向美國食品藥物管理局(FDA)成員展示使用者介面,包括各種選單畫面與血糖追蹤輸出。
Our continued goal is to complete all development, clinical, and regulatory efforts with at least one partner and be positioned to launch a first product during the summer of 2009, but as you are well aware, the timing of the regulatory process is uncertain. In the interim, we continue to work on an informal basis with each of our insulin-pump partners to promote our respective products within our target markets.
我們持續的目標是,與至少一家合作夥伴完成所有開發、臨床與法規工作,並在 2009 年夏季推出第一項產品;但如各位所熟知,法規審查流程的時程具有不確定性。在此期間,我們仍以非正式方式與各胰島素幫浦合作夥伴合作,在我們的目標市場中推廣彼此的產品。
We have long held that continual introduction of next-generation products with improved performance and patient convenience are key to the development and growth of the CGM category. As discussed previously, we completed a pivotal trial in December of '07 for our third-generation ambulatory system. However, we elected to delay filing a PMA supplement, as our analysis determined that our gen-three sensor, as built for the pivotal trial, was more expensive due to increased labor and materials, while offering only incremental performance gains over The Seven.
我們長期以來一直認為,持續推出具備更佳效能與患者便利性的次世代產品,是 CGM 類別發展與成長的關鍵。如先前所述,我們於 2007 年 12 月完成第三代攜帶式系統的關鍵性試驗。然而,我們選擇延後提交 PMA 補充申請,因為我們的分析顯示,用於關鍵性試驗的第三代感測器因增加人工與材料而成本較高,但相較 The Seven 僅帶來有限的增量效能提升。
Continued R&D efforts during Q1 and Q2 this year have resulted in the development of a modified gen-three sensor with improved performance and convenience without added cost. We are on track to complete a small additional clinical trial this quarter, with a PMA supplement filing to follow quickly thereafter.
今年第一季與第二季持續的研發工作,已促成一款經修改的第三代感測器,其在不增加成本的情況下提升了效能與便利性。我們正按計畫於本季完成一項小型追加臨床試驗,並在其後迅速提交 PMA 補充申請。
Keeping in line with generational iterations, we continue to make progress on our fourth-generation product. We expect this design to incorporate an enhanced membrane system for even greater accuracy and be suited for large-volume production.
在世代迭代方面,我們的第四代產品也持續取得進展。我們預期此設計將納入強化的薄膜系統,以達到更高的準確度,並適用於大批量生產。
Additionally, our fifth-generation sensor is currently being tested in animals, and we expect that the technology behind this design will first be introduced in an in-hospital system.
此外,我們的第五代感測器目前正在動物試驗中,我們預期此設計背後的技術將首先導入院內系統。
We are pleased to report that, at the request of Food and Drug Administration, we are participating in a program to develop a guidance document on the use of the Internet to allow users of medical devices to upgrade device firmware. We believe we were asked to participate in this program in large part due to our recent receipt of approval by FDA for Internet updating of our Seven system firmware.
我們很高興報告,應美國食品藥物管理局(FDA)要求,我們正參與一項計畫,以制定指引文件,說明如何使用網際網路讓醫療器材使用者升級裝置韌體。我們相信,FDA 邀請我們參與此計畫,很大一部分原因在於我們近期已獲 FDA 核准可透過網際網路更新 Seven 系統的韌體。
Finally, we continue to pursue a CE mark for The Seven. We are working with our notified body to review our quality systems and assist us in obtaining the CE mark. We submitted our technical file in the first quarter of 2008, and we plan to complete our ISO audit during the third quarter of this year. This would enable us to begin conducting clinical trials in Europe before the end of 2008.
最後,我們仍持續為 The Seven 取得 CE 標誌。我們正與公告機構合作,審查我們的品質系統並協助我們取得 CE 標誌。我們已於 2008 年第一季提交技術檔案,並計畫於今年第三季完成 ISO 稽核。這將使我們能在 2008 年底前開始在歐洲進行臨床試驗。
We continue to be extremely pleased with the result of our ongoing clinical studies for our in-hospital continuous glucose monitoring system. We were able to demonstrate outstanding prospective accuracy in our porcine models, often achieving 100% of data points, meeting the ISO standard for therapeutic use. We've made significant advances in our membrane technologies that will allow us to block the most common sources of drug-related interference in the critical setting, including acetaminophen. We're on track to complete our development efforts and conduct a pivotal trial before the end of 2008. We believe this would enable us to commercialize our first product in the critical-care setting in the second half of 2009.
我們對院內連續血糖監測系統正在進行的臨床研究結果仍感到非常滿意。我們在豬模型中展示了卓越的前瞻性準確度,經常達到 100% 的資料點符合 ISO 治療用途標準。我們在薄膜技術方面取得重大進展,可在重症情境下阻擋最常見的藥物相關干擾來源,包括乙醯胺酚(acetaminophen)。我們正按計畫在 2008 年底前完成開發工作並進行關鍵性試驗。我們相信,這將使我們能在 2009 年下半年於重症照護場域商業化推出第一項產品。
We remain committed to commercializing our in-hospital product through an established partner with experience in the critical-care market. We continue to engage in discussions with a number of potential business partners about opportunities to participate in the design, development, and commercialization of our system. We expect that a partner would provide a combination of upfront and milestone payments to support our R&D, clinical, and regulatory efforts for our first-generation stand-alone system, and we would expect to participate with the partner in the commercialization of the system.
我們仍致力於透過在重症照護市場具備經驗的既有合作夥伴,將院內產品商業化。我們持續與多家潛在商業合作夥伴洽談,探討參與我們系統設計、開發與商業化的機會。我們預期合作夥伴將提供預付款與里程碑款的組合,以支持我們第一代獨立式系統的研發、臨床與法規工作,且我們也預期將與合作夥伴共同參與該系統的商業化。
Additionally, much like our ambulatory product, we believe that the continual introduction of next-generation products with improved performance and convenience will be key to the development and growth of the in-hospital CGM category, and we expect to work diligently with our partner on the development of a fully integrated system.
此外,如同我們的攜帶式產品,我們相信持續推出具備更佳效能與便利性的次世代產品,將是院內 CGM 類別發展與成長的關鍵;我們也預期將與合作夥伴勤勉合作,開發一套完全整合的系統。
Based on the status of the current discussions with potential partners, we expect to complete technical and business due diligence and finalize negotiations with a chosen partner within the next 90 days.
根據目前與潛在合作夥伴討論的進度,我們預期在未來 90 天內完成技術與商務盡職調查,並與選定的合作夥伴完成談判定案。
In summary, we continue to believe that CGM will play an important role in diabetes management and will ultimately become the standard of care for glucose monitoring. At the initial meeting of the Diabetes Advocacy Consortium last month, the utilization of CGM was highlighted by several of the presenters as a tool that needs to be used more frequently to better manage the daily glycemic variability of patients afflicted with diabetes.
總結而言,我們仍相信 CGM 將在糖尿病管理中扮演重要角色,並最終成為血糖監測的照護標準。在上個月糖尿病倡議聯盟(Diabetes Advocacy Consortium)的首次會議上,多位講者強調 CGM 的使用,認為這是一項需要更頻繁使用的工具,以更好管理糖尿病患者每日的血糖變異。
We will continue to provide leadership to the development of the category, both on the ambulatory side and in the hospital setting, and we remain committed to developing a valuable and sustainable business franchise. We believe DexCom has emerged as a clinical, technology, and market leader in CGM, and we believe our experience of more than two years of commercialization and eight years of development has positioned us as a strong organization with a foundation of institutional knowledge in CGM that new entrants in the category will be required to replicate to compete with us going forward.
我們將持續在類別發展上提供領導力,無論是在門診端或醫院端,並且我們仍致力於打造一個具價值且可持續的業務特許經營。我們相信 DexCom 已在 CGM 領域成為臨床、技術與市場的領導者;同時,我們超過兩年的商業化經驗與八年的研發投入,使我們成為一個強健的組織,並在 CGM 上建立了制度性知識的基礎,而未來新進入者若要與我們競爭,將必須複製這些能力。
Thank you, and now I'll take questions.
謝謝,接下來我將開始回答問題。
Operator
Operator
Thank you. (OPERATOR INSTRUCTIONS)
謝謝。(接線員指示)
And our first question will come from Tom Gunderson with Piper Jaffray.
我們的第一個問題來自 Piper Jaffray 的 Tom Gunderson。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Hey, guys.
嘿,各位。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Hey, Tom.
嘿,Tom。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Hi. Let's start where you guys started, on Anthem WellPoint. And, Terry, I fully expect that you take your victory lap and say you got one in before the end of the year, but this one was so early, and you did, I believe, characterize it late last year or early this year as having a number of irons in the fire and you just didn't know which one would click but you thought the probability of getting one. Were you thinking Anthem WellPoint on January 1 of this year was the lead dog, and if not, you care to go double or nothing on getting a second one before the end of the year?
嗨。我們就從你們一開始提到的 Anthem WellPoint 談起。Terry,我完全預期你會繞場一圈慶祝,說你在年底前拿下一家;但這次來得太早了。而且我記得你在去年底或今年初曾形容當時有好幾個案子同時在推進,你不確定哪一個會先成,但你覺得拿下一家的機率很高。你在今年 1 月 1 日時是否認為 Anthem WellPoint 會是最有希望的那一家?如果不是,你願不願意再賭一次:年底前再拿下第二家?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
You're tough. First of all, no. If I were to categorize historical perspective on new technology adoption in the diabetes space by the entities that we encounter, I don't think that Anthem would have been the first one. That said, they were certainly in the top group.
你很犀利。首先,不是。如果我以我們接觸到的機構在糖尿病領域採用新技術的歷史角度來分類,我不認為 Anthem 會是第一個。話雖如此,他們確實在最前段的那一群之中。
No, I don't want to double down. I will take my victory lap at this point.
不,我不想加碼。我現在就先繞場一圈慶祝。
We do believe, though, Tom, in all sincerity, that this is driving the full course of events at a more rapid pace than we originally envisioned when we last spoke.
不過,Tom,我們真心相信,這件事正推動整個事件鏈以比我們上次談到時原先預期更快的速度發展。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. Thanks for that. And then, Abbott -- you have a third player on the market, and you didn't mention anything on competition during the prepared remarks so I'll ask you here.
好,謝謝。接著談 Abbott——市場上有第三個玩家,而你們在事先準備的發言中沒有提到競爭,所以我在這裡問。
Have you see any differences in the marketplace dynamic with Abbott, a third player out there, or anything that Medtronic MiniMed is doing that's changing, or are you all working together and separately to increase market size and get better reimbursement?
Abbott 作為第三個玩家加入後,你們是否看到市場動態有任何不同?或者 Medtronic MiniMed 的作法是否有任何改變?還是你們彼此既合作又各自努力,一起擴大市場規模並爭取更好的給付?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, I think if you -- I referred to the first meeting of the Diabetes Advocacy Consortium in which actually MiniMed was there, Abbott and Beck, LifeScan, Bayer, Rosch, Lilly, Synovia, Ventas, Novo Nordisk -- anybody in the space was there.
我想——我提到過糖尿病倡議聯盟(Diabetes Advocacy Consortium)的第一次會議,當時其實 MiniMed 也在場,Abbott、Beck、LifeScan、Bayer、Rosch、Lilly、Synovia、Ventas、Novo Nordisk——這個領域裡的各方幾乎都到齊了。
Clearly, the discussion by all parties was the utilization of intensive management, but particularly more on the CGM side than on the pump side, about ways in which to drive this awareness to a greater degree and looking at, unfortunately, the rapid rise of diabetes, not only on the type 2 segment, but we're also seeing, unfortunately, a rise in the organic growth of type 1. I think everybody was participating to the good of the category. I didn't see any differentiation from that standpoint.
很明顯,各方討論的重點是強化密集管理(intensive management)的使用,但特別是在 CGM 端而非幫浦端,探討如何更大幅度地提升這方面的認知;同時也關注糖尿病的快速上升,不僅在第 2 型族群,我們也不幸看到第 1 型的自然成長率也在上升。我認為大家都是以促進整個類別發展為出發點參與其中。從這個角度我沒有看到任何差異化。
I think from Abbott joining the -- it can only be good news because it will add more weight to the category and more validation of the category, but we haven't seen -- they haven't been out long enough to see any issues that we've addressed yet.
我認為 Abbott 加入——只會是好消息,因為它會為這個類別增加分量並帶來更多驗證;但我們還沒有看到——他們上市時間還不夠長,因此目前還看不到我們需要去因應的任何問題。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. And then last question and I'll get back in line.
好。最後一個問題,我就回到隊伍後面。
You were focused in your first six months on the top 50 -- you expanded that to the top 100 centers that you want your field force focusing on. Can you give us a sense, after almost a year with this focus on the top top centers, are there ones out there that are free to go and you've moved on; in other words, they don't get the same sort of intense visits on training and usage that they did in the early days?
你們在前六個月聚焦於前 50 大中心——之後擴大到前 100 大中心,讓你們的業務團隊重點投入。能否談談,在將近一年聚焦於這些頂尖中心之後,是否有一些中心已經「搞定」了、你們就轉往其他地方?換句話說,他們不再像早期那樣接受密集的拜訪、訓練與使用推動?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
That's correct. I mean, when we had to drive the whole concept of utilization of this tool, we were spending more than normal amount of time in any one center. But we -- my goal there, as stated before, was we've got to stay there long enough to drive adoption, not just get the key opinion leader or the chairman of the diabetes group there to be a believer. I think we had -- over the last year or so -- been able to do that effectively. We needed to get down within the organization, both prescribers as well as the diabetes educators, to begin to look at what the utilization -- how are they changing the behavior patterns of the patients utilizing the CGM in order to better manage their diabetes.
沒錯。我的意思是,當我們必須推動大家接受並使用這個工具的整體概念時,我們在任何一個中心投入的時間都比一般情況更多。但——我先前也說過——我的目標是:我們必須在那裡待得夠久,才能真正推動採用,而不只是讓關鍵意見領袖或該中心糖尿病團隊的主任成為支持者。我認為我們在過去一年左右已經有效做到這點。我們需要深入到組織內部,讓開立處方的醫師以及糖尿病衛教師都開始關注使用方式——他們如何透過使用 CGM 來改變病人的行為模式,以更好地管理糖尿病。
I think we've done just truly an outstanding job. We were able to expand beyond where we're at now. I think, in addition -- I mean, I mentioned that in covered areas we would certainly go to those sites that had large populations that were covered by a particular third-party payer. In addition, we are doing joint sales calls now with our pump partners, and in the event that we're -- they happen to be calling on somebody or a center that is outside of our target, we certainly have released our salespeople to be able to go complement the respective pump partner.
我認為我們確實做得非常出色。我們也得以擴展到目前之外的範圍。我想,另外——我的意思是,我提到過在已涵蓋的區域,我們當然會去那些由特定第三方付款方所涵蓋、且病患量很大的據點。此外,我們現在也會與我們的幫浦合作夥伴進行聯合拜訪;若他們剛好拜訪到某位醫師或某個中心不在我們的目標名單內,我們也會讓我們的業務人員前往配合,補強相應的幫浦合作夥伴。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. Great. Thank you.
好。非常好。謝謝。
Operator
Operator
And next we'll hear from Mimi Pham with JMP Securities.
接下來我們聽取 JMP Securities 的 Mimi Pham 提問。
Mimi Pham - Analyst
Mimi Pham - Analyst
Hi. Good afternoon. On the J & J and OmniPod integration timelines, is there any reason why the timelines would be any different between the two?
嗨,下午好。關於 J & J 與 OmniPod 的整合時程,是否有任何原因會讓兩者的時程不同?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Mimi, the main thing would be the -- quite frankly, would just be the amount of effort that would be thrown towards one or the other. I mean, as we've described previously, what we have to do is really create a new circuit board and then populate that circuit board with additional software. And from that, that takes a lot of engineering time in order to do that and still try to remain within the footprint of both the J & J Animas pump, the 2020, as well as the patient programmer from Insulet.
Mimi,主要因素會是——坦白說——投入到其中一方或另一方的工作量。我們先前描述過,我們必須真正打造一塊新的電路板,然後在那塊電路板上加入額外的軟體。要做到這些需要大量工程時間,同時還要盡量維持在 J & J Animas 2020 幫浦以及 Insulet 的病患程式器(patient programmer)的既有外形尺寸限制之內。
I would just say at this point, obviously, if you look at the size of the organizations, one has more resources that they can allocate to that effort than the others just based on their R&D resources.
我只能說,就目前而言,顯然如果你看組織規模,其中一家基於其研發資源,能投入到這項工作的資源會比另一家更多。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. And you mentioned that 1,500 three-day users have upgraded so far. It sounds like you expect that number of upgrades to drop off. Does this mean that the other 2,000 or so people who bought the three-day aren't using the system anymore?
好。你提到目前已有 1,500 位三日使用者完成升級。聽起來你預期升級數量會開始下滑。這是否表示其他大約 2,000 位購買三日版本的人已經不再使用這套系統?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
That's a correct assumption.
這個推論是正確的。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. And then, last, on WellPoint, when did you actually start that process -- if you can give us more color -- and how involved were you along the way? Did they call you -- were you in contact every few months or --
好。最後,關於 WellPoint,你們實際上是何時開始那個流程——如果你能提供更多細節——以及你們在過程中參與的程度如何?是他們打給你們——你們是否每隔幾個月就保持聯繫,或是——
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
So, Mimi, I'm not -- this is Steve. I'm not really sure how to answer --
所以,Mimi,我不——我是 Steve。我不太確定該怎麼回答——
Mimi Pham - Analyst
Mimi Pham - Analyst
Oh, okay. Did you put in a formal request, I guess, on a certain day or time? I just wanted to get a sense of how long.
喔,好。我的意思是,你們是否在某一天或某個時間點提出正式申請?我只是想了解大概花了多久。
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
No. It isn't that simple. So, as we've spoke to you before, we have a field-base team. There's four individuals who are employed by DexCom who work out in the field and are charged exclusively with calling on the private-payer system, and these folks, obviously -- we have one person who's specifically assigned to Anthem WellPoint as a national payer, but then you keep in mind that Anthem network is broadly stretched across the country into regions. So there are multiple call points within the Anthem network.
不,事情沒那麼簡單。所以,正如我們之前跟你說過的,我們有一個以外勤為主的團隊。有四位由 DexCom 雇用的人在外勤工作,專責拜訪民間付款方體系;而這些人——顯然——我們有一位專門負責 Anthem WellPoint 這個全國性付款方,但你也要記得 Anthem 的網絡廣泛分布全國各地、分成不同區域。因此在 Anthem 網絡內有多個拜訪接觸點。
So to answer that question, it wasn't like a single meeting that drove this by any means. It's months of effort on our part. Frankly, I have to assume there's efforts on Medtronic part. The Juvenile Diabetes Research Foundation has been outstanding in their support of helping push forward the coverage policy. And on top of that, it's our collective efforts, I think, between DexCom's internal reimbursement efforts to hit the payer system with one-off claims, and I have to believe Medtronic -- we understand that Medtronic is doing the same thing. It raises the level of awareness within the Anthem network to rise up to the level of the national policy decision.
所以要回答那個問題,這絕不是由單一會議所促成的。這是我們數個月來的努力。坦白說,我也必須假設美敦力那邊也有相應的努力。青少年糖尿病研究基金會在支持並協助推動給付政策方面表現非常出色。除此之外,我認為這也是我們的共同努力:DexCom 內部的給付/報銷團隊透過向付款方系統提出單筆個案理賠來推進;而我也相信美敦力——我們了解美敦力也在做同樣的事情。這提高了 Anthem 網路內的認知程度,進而提升到全國性政策決策的層級。
And that's kind of how the decision came about. So we couldn't tell you it was a meeting that led up to it or some single trigger point. Does that make sense?
而這大概就是這項決定形成的方式。所以我們無法告訴你是某一次會議導致的,或是某個單一觸發點。這樣說有道理嗎?
Mimi Pham - Analyst
Mimi Pham - Analyst
Yes. It's makes sense. Thank you so much for the clarification.
是的。這很有道理。非常感謝你的說明。
Operator
Operator
And next we'll take a question from Ben Andrew with William Blair.
接下來我們將接聽 William Blair 的 Ben Andrew 的提問。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Good afternoon. It's actually Matt in for Ben.
下午好。其實我是 Matt,代 Ben 發問。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Hey, Matt.
嗨,Matt。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Hey. How you doing?
嗨。你最近如何?
On the Anthem side of things, when you talk about having this kind of national coverage decision and how going forward a little bit, it sounds like it's going to be on a region-by-region basis of building out those contracts. First of all, is it going to be specific to DexCom, that you have to get a contract for DexCom CGM's, or is it going to be a broad contract?
關於 Anthem 這邊,當你談到這種全國性的給付決定,以及未來聽起來會以逐區域方式建立那些合約。首先,這會是針對 DexCom 的嗎,也就是你們必須為 DexCom 的 CGM 取得合約?還是會是一個更廣泛的合約?
And then can you just kind of talk about the process of going through and convincing the specific regions? I mean, how much convincing do you think is going to need to occur before you start getting these regional contracts in place?
另外,你能否談談說服各個特定區域的流程?我的意思是,在你們開始把這些區域合約落地之前,你覺得需要做多少說服工作?
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Sure, Matt. This is Steve. So it's actually unique. In the Blue Cross network, it's actually really interesting the way they process claims. They way they process claims, since we sit as DexCom as a provider in the state of California, we're actually required to process our claims through Blue Cross of California, which is a member of the WellPoint network.
當然可以,Matt。我是 Steve。其實這很獨特。在 Blue Cross 網路中,他們處理理賠的方式非常有意思。他們處理理賠的方式是:由於 DexCom 在加州是以提供者(provider)的身分存在,我們實際上必須透過加州的 Blue Cross(Blue Cross of California)來處理理賠,而它是 WellPoint 網路的一員。
So we're still looking into whether we would need to contract on an individual basis with each of the WellPoint entities, but in short order, it's most important for us to contract in California to be able to process claims through the California Blue Cross affiliate, which would enable us then to process claims basically across the country throughout their network.
所以我們仍在研究是否需要與每一家 WellPoint 實體逐一簽約;但短期內,對我們最重要的是先在加州完成簽約,才能透過加州 Blue Cross 的關係企業處理理賠,進而讓我們基本上能在全國範圍內透過他們的網路處理理賠。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. And then on the question as far as specific to DexCom, or is it going to be more broad just CGM category in general?
了解。那回到剛才那個問題:這是針對 DexCom,還是更廣泛、針對整個 CGM 類別?
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
The coverage policy is broad with respect to CGM. The next step is for DexCom to secure a contract that -- it's a contract that dictates the terms under which we do business with Anthem, and it would have a pricing schedule attached and so on and so forth.
給付政策在 CGM 方面是廣泛適用的。下一步是 DexCom 需要取得一份合約——這份合約規範我們與 Anthem 往來的條款,並會附帶價格表等內容。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Sure. Any shot at the number of lives that that national decision would cover?
好的。那這個全國性決定大概涵蓋多少受保人數(lives)?有沒有機會給個數字?
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Well, we've done the research on it, and I would say it appears that it is not just Anthem but the entire WellPoint network, which could be as many as approximately 34 million covered lives is what they state publicly as their number of covered lives. But we don't have confirmation on that. We know it's certainly the Anthem -- the group of Anthem payers that are listed on the coverage policy itself, but we have our researchers been able to cover the similar policy decision on a number of the other Anthem -- or, should I say, WellPoint entities that are not listed specifically under the Anthem label.
我們做過相關研究,我會說看起來不只是 Anthem,而是整個 WellPoint 網路;他們公開宣稱的受保人數可能多達約 3,400 萬。但我們沒有得到確認。我們知道至少涵蓋 Anthem——也就是給付政策本身所列出的那一組 Anthem 付款方;但我們的研究人員也能在一些其他 Anthem——或者我應該說 WellPoint——實體上,找到類似的政策決定,而那些實體並未明確列在 Anthem 這個標籤之下。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. And then on the medical-necessity side, you guys are getting reimbursement on a one-off prior to this decision. How does this decision compare on a medical-necessity basis to the patients that were already getting reimbursed?
了解。那在醫療必要性(medical necessity)方面,你們在這項決定之前就已經能以單一個案取得報銷。這項決定在醫療必要性的標準上,和那些原本就能獲得報銷的病患相比,有什麼不同?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, in many cases it's very consistent. If you really look at a patient with diabetes, and regardless if they're on multiple daily injections or pump therapy, a fair number of patients would qualify under this medical necessity because, in spite of best efforts -- and heretofore we've always used A1c as a criteria to demonstrate acceptable glucose control. We know that A1c is highly variable because of the average nature of it.
嗯,在很多情況下其實非常一致。如果你仔細看糖尿病患者,不論是多次每日注射(MDI)或幫浦治療,相當多患者都可能符合這個醫療必要性的條件,因為即使盡了最大努力——而且過去我們一直用 A1c 作為判準來證明可接受的血糖控制——我們知道 A1c 因為其「平均值」的特性而具有高度變異性。
I would say that, although in a category -- anything to do with hypoglycemia gets faster reimbursement than some other category. But I think everybody has hypoglycemia daily. When we begin to look at all of the chartings on the clinical trials that we conduct and everything that is published by either Medtronic or Abbott, you see most of the patients in those well-controlled clinical trials having some degree of repetitive hypoglycemia on a daily basis. The goal is to try to stay between the lines the best -- especially on patients who are intensively managed, as you bring the bar down, unfortunately, the bottom of that bar typically will range into the hypoglycemic arena.
我會說,雖然在某些類別中——任何與低血糖(hypoglycemia)相關的項目,通常比其他類別更快獲得報銷。但我認為每個人每天都會發生低血糖。當我們開始檢視我們所做的所有臨床試驗圖表,以及美敦力或雅培所發表的所有資料時,你會看到在那些控制良好的臨床試驗中,多數患者每天都會有某種程度的反覆低血糖。目標是盡可能維持在界線之間——尤其對於密集管理的患者,當你把目標門檻往下調時,不幸的是,那個門檻的下緣通常就會落入低血糖的範圍。
So I think there are -- again, it depends on how the physicians characterize it in their particular practice, how the documentation is completed in order to justify the reimbursement.
所以我認為——再次強調,這取決於醫師在其特定診療實務中如何描述,以及為了合理化報銷而完成的文件紀錄方式。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. And then on the hospital product, last quarter you gave us some data from the first animal testing, and it's rather astounding, actually, with the number of data points hitting the region A of the [carc] air grid. Do you have any updates, I mean, from where you were at last quarter to this quarter? It sounded like most of the data points are still in region A from the latest testing that you've done.
了解。那關於院內產品(hospital product),上季你們給了我們第一輪動物測試的一些數據,實際上相當驚人,因為有大量數據點落在 [carc] air grid 的 A 區。你們有沒有更新?也就是從上季到這季的進展?聽起來你們最新的測試中,大多數數據點仍然在 A 區。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
That's correct. We've done an additional porcine model -- and in fact one is going on today -- and to that we -- a number of our visitors who are not DexCom employees want to see that. So from that standpoint, obviously, in these discussions that I've outlined, they believe that's a degree of proof of concept. So we continue to do that. We continue to impress them and ourselves.
沒錯。我們又做了一個額外的豬隻模型(porcine model)——事實上今天就有一個正在進行——而且有一些來訪者(不是 DexCom 員工)想要觀看。因此就我剛才概述的那些討論而言,他們相信這在某種程度上證明了概念可行性(proof of concept)。所以我們會持續做下去,也持續讓他們以及我們自己感到印象深刻。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. And then one quick last one. With Abbott on the market now, any update on the litigation side? I mean, we haven't talked much about that at all in recent quarters. With them out there now -- and that had been one of the gating factors to them suing you guys. Have you seen any more increase in activity in terms of what the lawyers are up to?
了解。最後再快速問一個。雅培現在已經在市場上了,訴訟方面有沒有任何更新?我的意思是,我們最近幾季幾乎沒怎麼談這件事。現在他們已經出來了——而那曾是他們起訴你們的一個門檻因素——你們有看到律師那邊在活動上有任何增加嗎?
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Not on the litigation side, Matt. As you know, the case is stayed in Delaware, and the judge has made it fairly clear that he's going to keep the case stayed until all seven patents that are subject in the litigation come out of the reexamination proceeding. I would say those seven patents are in various stages of reexamination at this point.
訴訟方面沒有,Matt。如你所知,案件在德拉瓦州被暫停(stayed),而法官已相當明確表示,在訴訟所涉及的七項專利全部完成再審查程序(reexamination proceeding)之前,他會維持案件暫停。我會說,這七項專利目前正處於不同的再審查階段。
I couldn't give you any guidance on the timing there. It's fully within the control of the PTO. It could be months, it could be a year or years. I really have -- we just don't know. We have some visibility, but these proceedings are all done an ex parte basis, which means we basically file some documents, and then they turn around and file some documents. And so there's not an interaction, per se, before the PTO. It's really -- in that respect, it's largely out of our control.
我無法就時間點給你任何指引。這完全在美國專利商標局(PTO)的掌控之中。可能是幾個月,也可能是一年或數年。我真的——我們就是不知道。我們有一些能見度,但這些程序都是以單方(ex parte)的方式進行,也就是我們基本上提交一些文件,然後對方再提交一些文件。因此在 PTO 面前並不存在所謂的互動。就這點而言,基本上很大程度不在我們的控制範圍內。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. Great. Thank you very much.
好的。很棒。非常感謝。
Operator
Operator
And next question will come from Ben Andrew's location.
下一個問題將由 Ben Andrew 所在地提出。
Ben Andrew - Analyst
Ben Andrew - Analyst
Hi. Can you guys here me?
嗨。你們聽得到我嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes.
是的。
Ben Andrew - Analyst
Ben Andrew - Analyst
Hi. Matt jumped on as me, I guess, and I was listening as well.
嗨。我想 Matt 以我的身分加入了,我也一直在聽。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
You sound different, Matt.
你聽起來不一樣了,Matt。
Ben Andrew - Analyst
Ben Andrew - Analyst
Well, we're confusing each other at this point.
嗯,我們現在把彼此搞混了。
He actually got my questions. There's only a couple of things I wanted to follow up on.
他其實拿到了我的問題。我只有幾件事想追問。
Terry, should we assume that that 1,500 conversion number represents the bulk of the patients that were left on the STS-3, and how many were converted previous (inaudible)?
Terry,我們是否可以假設那個 1,500 的轉換數字代表 STS-3 上剩下的大多數病患?那之前(聽不清)轉換了多少?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
It's cumulative so that would be the bulk of what was left on the STS-3.
那是累計數,所以那會是 STS-3 上剩下的大部分。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. So would you suggest we sort of take the 1,500 plus the 1,207 plus the last couple quarters and come up with an install base, or is that not a good --
好的。所以你會建議我們把 1,500 加上 1,207 再加上最近幾季的數字,算出一個裝機基礎(install base)嗎?還是那不是個好——
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Would I suggest that? That would be tough for me to suggest that. I can't -- but, I mean, I think we have been straightforward in preparing you to do that analysis.
你問我會不會建議那樣做?我很難建議。我不能——不過,我的意思是,我想我們一直很坦率地讓你們可以做那樣的分析。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. That's fair. What are you seeing right now in terms of the usage of The Seven? Is it still north of seven days and maybe something around ten days for the average patient as you get a little bit larger population that's preordering?
好的。這很公平。你們目前看到 The Seven 的使用情況如何?平均每位病患仍然超過七天,可能大約十天嗎?尤其是當預訂的人口變得更大時?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, we do tend to see that. In fact, I mentioned in my earlier comments, we've most recently been at -- with the Food and Drug Administration we found out that a number of those individuals are wearing our Seven product, and as a result of that, they communicated to us that they're wearing it for seven to ten, beyond days. We're continuing to see that.
是的,我們確實傾向看到那樣。事實上,我在先前的評論中提到,我們最近——與美國食品藥物管理局(FDA)交流時發現,其中一些人正在配戴我們的 Seven 產品;因此,他們也告訴我們,他們配戴時間是七到十天,甚至超過七天。我們仍持續看到這種情況。
Obviously, at the ADA you'll see a paper of a clinical trail sponsored by an investigator comparing The Seven at four, seven, and ten days, and showing no deterioration of accuracy over that ten-day period.
顯然,在 ADA 你會看到一篇由研究者主導、贊助的臨床試驗論文,比較 The Seven 在四天、七天與十天的表現,並顯示在十天期間準確度沒有惡化。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. It's interesting the FDA staff (inaudible) be wearing to promote The Seven, but I guess that's --
好的。很有意思,FDA 的人員(聽不清)在配戴來推廣 The Seven,但我想那就是——
Terry Gregg - President and CEO
Terry Gregg - President and CEO
It's the best product on the market so I guess they migrated to that.
它是市面上最好的產品,所以我想他們就轉用那個了。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. I'll jump out. Thank you very much.
好的。我先退出。非常感謝。
Operator
Operator
And next we'll hear from Bill Plovanic with Canaccord Adams.
接下來我們將聽取來自 Canaccord Adams 的 Bill Plovanic。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Great. Thank you. Can you hear me?
很好。謝謝。你們聽得到我嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, Bill.
聽得到,Bill。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Fantastic. Sorry -- I'm in an airport.
太好了。抱歉——我在機場。
Two questions. First, again, point of clarification. So you have about 2,000 patients that have not upgraded to the STS, or you have about 500 or so? What -- I didn't --
兩個問題。第一,再次釐清一下。所以你們大約有 2,000 位病患尚未升級到 STS,還是大約 500 位左右?我——我沒有——
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Bill, we haven't given any guidance on that. I will tell you, we'll just stick to the over 1,500 have upgraded from the STS-3 to The Seven System and leave it at that.
Bill,我們沒有就此提供任何指引。我只能告訴你,我們就維持在『超過 1,500 位已從 STS-3 升級到 The Seven System』,就先說到這裡。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Cumulatively, that's what you're saying?
你說的是累計嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Cumulatively, correct.
累計,沒錯。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. Great. That's clarification.
好的。很好。這就釐清了。
And then number two, in terms of the porcine studies, how many incremental kind of drugs or fluids have been tested on those animals, because it's my understanding, when you get into the hospital market especially, there's a lot of confounding factors that can impact the readings that you're getting?
第二,關於豬隻研究(porcine studies),你們在那些動物身上額外測試了多少種藥物或輸液?因為據我了解,尤其進入醫院市場時,有很多混雜因素會影響你們取得的讀值。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
We're going through that series of various drugs now. We've put together a list of about somewhere between a dozen and dozen and a half. Obviously, the one that we were most concerned with was acetaminophen. That's the most prevalent use of any particular drug in that setting, and we have demonstrated a complete resistance to any interference with that. And there are others, but that was the one that we were most concerned about.
我們正在進行各種藥物的那一系列測試。我們整理了一份清單,大約在 12 種到 18 種之間。顯然,我們最關切的是乙醯胺酚(acetaminophen)。在那種場域中,它是使用最普遍的特定藥物,而我們已證明對其干擾具有完全的抗性。還有其他藥物,但那是我們最關心的一個。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
I mean, is there any one drug that has a propensity to actually negatively impact readings, because, as you said, acetaminophen is most used, but it might not be the one that's most likely to impact --
我的意思是,有沒有任何一種藥物特別容易對讀值造成負面影響?因為如你所說,乙醯胺酚使用最廣,但它可能不是最可能造成影響的那一個——
Terry Gregg - President and CEO
Terry Gregg - President and CEO
No. Acetaminophen is the one -- the reason we focused. Not only is it the most used, it's the one that causes the greatest degree of sensor inaccuracy.
沒有。乙醯胺酚就是那個——我們之所以聚焦的原因,不只是因為它最常用,它也是造成感測器不準確程度最大的那一個。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. Great. That's all I have. Thanks a lot. I'll see you at my conference in a month.
好的。很好。我就這些。非常感謝。下個月在我的研討會見。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
You got it.
沒問題。
Operator
Operator
(OPERATOR INSTRUCTIONS)
(接線員指示)
And we'll hear from Stephan Ogilvie with Thinkpanmure.
接下來我們將聽取來自 Thinkpanmure 的 Stephan Ogilvie。
Diego Huerta - Analyst
Diego Huerta - Analyst
Hi. This is [Diego Huerta] filling for Stephan.
嗨。我是 [Diego Huerta],代 Stephan 發言。
I just have one question. With the hospital base product and the collaborative project, is there a way to monetize these activities before commercial launch?
我只有一個問題。關於醫院基礎產品與合作專案,在商業化上市之前,有沒有辦法將這些活動變現?
Thank you.
謝謝。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, absolutely. The way in which any partnership would be structured, there will be upfront payments in order to engage in a relationship subsequent to that, and outlined will be a series of milestone payments that cover our R&D costs, as well as our regulatory costs as it relates to conducting clinical trials. And then as part of that structure, there will also be some type of royalty stream, to speak of, or profit sharing on a commercializable basis.
是的,絕對可以。任何合作夥伴關係的架構方式,都會包含為了建立後續合作關係而支付的前期款項;此外,也會規劃一系列里程碑款項,用以涵蓋我們的研發成本,以及與進行臨床試驗相關的法規/監管成本。然後在該架構中,也會有某種形式的權利金收入(royalty stream),或以可商業化為基礎的利潤分成。
Diego Huerta - Analyst
Diego Huerta - Analyst
Thank you. That's all.
謝謝。就這些。
Operator
Operator
(OPERATOR INSTRUCTIONS)
(接線員指示)
And there appear to be no further questions at this time.
目前看來沒有其他問題。
Gentlemen, I'll turn the conference back to you for any additional or closing remarks.
各位先生,我把電話會議交回給你們,請作任何補充或結語。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thank you. Again, appreciate you taking the time this afternoon to listen to our first quarter 2008 conference call. Obviously, we've made tremendous progress from the last time we spoke. We've really got the engine in high gear doing a lot of interesting things in a lot of different spaces all related to improvement of glycemic variability, which we believe is one of the single most difficult things to achieve and actually has the best payoff for patients in the ambulatory world suffering with diabetes and in the surgical ICU and areas outside. We are not restricted to only patients with diabetes because hyperglycemia as a result of stress is also hugely impactful in terms of morbidity, mortality, time spent in the hospital, and particularly in a DRG-based environment in the hospital getting them out of the hospital a day earlier is obviously beneficial to the payer system.
謝謝。再次感謝各位今天下午撥冗收聽我們 2008 年第一季的電話會議。顯然,自上次通話以來我們取得了巨大的進展。我們確實已經把引擎拉到高速檔,在許多不同領域做了很多有趣的事情,而這些都與改善血糖變異(glycemic variability)相關;我們相信這是最難達成的目標之一,但對於門診世界中罹患糖尿病的病患,以及外科加護病房(surgical ICU)與其他領域的病患而言,回報也最大。我們不僅限於糖尿病病患,因為壓力所導致的高血糖(hyperglycemia)在發病率、死亡率、住院天數等方面也有極大的影響;尤其在醫院採用 DRG(診斷關聯群)為基礎的環境下,讓病患提早一天出院,對支付方體系顯然是有利的。
So I will conclude, and, again, thanks, and look forward to the next quarter call.
我就此作結,再次感謝,並期待下一季的電話會議。
Operator
Operator
And, again, that does conclude today's conference call. Thank you for your participation. Have a wonderful day.
再次說明,今天的電話會議到此結束。感謝各位的參與。祝各位有美好的一天。